CUE Cue Biopharma
Company Analysis
Latest News
🟢 Cue Biopharma is trading 5.65% up in pre-market with no confirmed catalyst
Cue Biopharma is trading at $26.00, up 5.65%, in pre-market, with the reason for the move unconfirmed. - Cue Biopharma closed at $24.61 on October 12,...
🔴 Cue Biopharma is trading 10% down with no clear company-specific catalyst
Cue Biopharma is trading 10.25% down at $24.82, with no clear company-specific catalyst identified for the October 12 decline. - Cue Biopharma’s...
🔴 Cue Biopharma is trading 5.6% down; no clear catalyst identified
Cue Biopharma is trading at $26.10, down 5.64%, with no clear catalyst identified for the October 12 decline. - No company-specific announcement or clear...
🟢 Cue Biopharma is trading 12% up with no identified company-specific catalyst
Cue Biopharma is trading at $25.00, up 11.96%, with no clear company-specific announcement identified to explain the October 9 move. - Recent CUE-221 trial...
🟢 Cue Biopharma is trading 6.6% up; immediate catalyst remains unclear
Cue Biopharma is trading at $23.81, up 6.63%, with no clear immediate catalyst identified for the October 9 move. - No company-specific announcement...
🔴 Cue Biopharma is trading 5.5% down amid biotech-sector weakness
Cue Biopharma is trading 5.5% down at $23.01 on October 6, 2026; biotech-sector weakness may be contributing, though no clear company-specific catalyst was...
🔴 Cue Biopharma is trading 11% down with no identified company-specific catalyst
Cue Biopharma is trading 11.03% lower at $22.75 on October 5, 2026; no company-specific announcement explaining the decline was identified. - The company’s...
🔴 Cue Biopharma is trading 6.8% down
Cue Biopharma is trading at $23.82, down 6.84%, with no clear company-specific announcement explaining the October 5 decline. - Available company news...
🟢 Cue Biopharma is trading 5.5% up with no confirmed catalyst
Cue Biopharma is trading at $26.92, up 5.53%, with no confirmed explanation for the September 30, 2026 move. - No new company-specific announcement explaining...
🔴 Cue Biopharma is trading 10% down; no clear catalyst identified
Cue Biopharma is trading 10.31% lower at $24.62, with no clear company-specific catalyst identified for the September 29 decline. - Positive CUE-221 Phase 2...
🔴 Cue Biopharma is trading 5% down with no clear catalyst identified
Cue Biopharma is trading 5.17% lower at $26.03; no company-specific announcement or clear catalyst was identified for the September 29 decline. - Positive...
🟢 Cue Biopharma is trading 5.7% up in pre-market with no identified catalyst
Cue Biopharma is trading 5.7% up at $29.00 before the September 29, 2026 session; no specific cause has been established. - The latest major company news...
🔴 Cue Biopharma is trading 10% down today as U.S.-Iran stalemate lifts oil and Treasury yields
Cue Biopharma is trading at $28.25, down 10.05%, alongside broad market weakness tied to inflation and rate concerns. - No clear company-specific announcement...
🔴 Cue Biopharma is trading 5% down today as oil and Treasury yields rise
Cue Biopharma is trading at $29.81, down 5.09%, amid broader market weakness. - No clear new company-specific catalyst was identified for September 28;...
🔴 Cue Biopharma is trading 6.8% down in pre-market
Cue Biopharma is trading 6.8% lower at $29.28 pre-market; the immediate catalyst is uncertain. - Positive Phase 2 CUE-221 results announced September 20...
Cue Biopharma Gets Strong Sell Downgrade from Wall Street Zen
Wall Street Zen downgraded Cue Biopharma (NASDAQ:CUE) from sell to strong sell in a research note issued Saturday. The downgrade followed a volatile week for...
🔴 Cue Biopharma is trading 5.3% down today with no clear company-specific catalyst identified
Cue Biopharma is trading 5.3% down at $31.11 during live trading on September 25, 2026, with no clear company-specific catalyst identified. - Its latest major...
🟢 Cue Biopharma is trading 9.98% up today in pre-market after CUE-221 met Phase 2 primary endpoint
Cue Biopharma is trading 9.98% up now at $36.13 as investors continue reacting to positive September 20 topline Phase 2 results for CUE-221. - The study met...
🟢 Cue Biopharma is trading 5.3% up today after statistically significant CUE-221 Phase 2 efficacy results
Cue Biopharma is trading at $33.39, up 5.30%, rebounding after positive CUE-221 Phase 2 results announced September 20, which showed statistically significant...
🔴 Cue Biopharma is trading 2% down in pre-market as broader market weakness pressures biotech shares
Cue Biopharma is trading 2% down at $31.10 as broader U.S. market weakness pressures risk-sensitive biotechnology shares. - The Nasdaq Composite is down 0.86%...